Cutting basic research kills export companies that have not been founded yet

New Zealand’s science reforms have a defensible logic and a dangerous blind spot. The government is squeezing an inefficient research system to chase near-term commercialisation. The problem, as Dr Nicola Gaston, director of the MacDiarmid Institute and a University of Auckland physicist, puts it, is that it is “like pulling an apple tree up by the roots to harvest its fruit.”

For B2B readers who think in terms of pipelines and pipelines of investable assets, that metaphor is the whole story. Defund the basic research and you don’t just lose academic output. You lose the deep-tech companies that were going to spin out of it in five years’ time.

The government’s case is real

Start with what the reforms get right. New Zealand’s research overhead rates have long been an outlier. The expert commentary points to university overheads running at 200 to 400 percent, against roughly 25 percent in Europe, meaning more than two dollars flow to institutional operations for every dollar of researcher salary. In Crown Research Institutes the ratio has run around four times salary. That is not a rounding error. It is a structural inefficiency worth attacking.

So the restructure has a genuine target. AgResearch, Manaaki Whenua, Plant & Food Research and Scion have been merged into the new Bioeconomy Science Institute. Callaghan Innovation is being disbanded, replaced by new Public Research Organisations built around four priority pillars: primary industries and bioeconomy, technology for prosperity, environmental resilience, and healthy people. Prime Minister Christopher Luxon’s stated ambition is to “brutally commercialise” science. Fair enough as a slogan.

Where the logic breaks

The question is whether the savings come from cutting waste or cutting seed-corn. On the evidence, some of it is seed-corn.

The reform includes secret cuts to the Endeavour Fund to finance a new Applied Technology Institute, and the abandonment of the National Science Challenges. That matters because the Endeavour and Marsden funds are exactly the kind of patient, unglamorous basic research that private investors will never touch, because at the time the science is done, nobody knows what it is for.

And that is the point most commercialisation rhetoric misses. Olivia Ogilvie, co-founder and CEO of Opo Bio, a MacDiarmid alumna building high-performance collagen, describes the deep-tech path: “Most startup advice tells you to start with the problem. But deep tech doesn’t work that way. You start with an invention, and then go looking for the best problem it can solve.”

Three companies the pillar system would have killed

Gaston offers three case studies from the MacDiarmid portfolio, and each one detonates the idea that you can pick winners at the funding stage.

Liquium now makes catalytic materials that cut the energy and carbon cost of ammonia production, useful for fertiliser and zero-carbon fuel. The original research targeted electronic devices. Quantum materials became clean tech. Orbis Diagnostics launched as “point-of-cow” testing for milk protein and fat, then pivoted to build the world’s first point-of-care Hepatitis B test. Advemto grew out of Marsden grants for solar photovoltaic research, and found its commercial opening in life sciences.

The pattern is unmistakable. Basic research funded in one sector produces a company in a completely different one. The government’s four pillars would have funded none of these at inception, because at inception none of them looked like what they became.

The talent walks first

The near-term cost is people. Across the restructured agencies, more than 600 scientists and researchers have been shed or are at risk. The Bioeconomy Science Institute confirmed 134 voluntary redundancies, on top of 152 roles axed at AgResearch, Scion and Landcare before the merger. At least 75 skilled Callaghan staff covering AI, biotech and medtech face redundancy before the fourth PRO meant to house them even exists.

Specialists who leave for countries that still fund their fields do not come back. And a fourth PRO announced today does nothing for a researcher who takes a Singapore offer next month.

What this means for the pipeline

Efficiency gains that come from trimming genuine overhead are savings. Gains captured by cutting Endeavour and Marsden are not. They are the destruction of investable assets that have not been created yet. The next generation of higher-value New Zealand exporters is, right now, sitting in university labs doing work that looks like it belongs in a different industry. Whether they survive to become fundable companies depends entirely on whether the basic research funding survives the next 12 to 18 months of restructuring. The government wants fruit. It is digging up the tree to get it faster.

Sources

• Govt science reform uproots the tree it needs to bear fruit (2026-07-30)
• Govt kept secret cuts to science funding to finance new Applied Tech Institute
• Further Cuts Fund New Tech Institute – Expert Reaction
• Newly Formed Bioeconomy Science Institute To Cut 134 Jobs
• Govt science jobs exodus ramps up – 134 jobs going at new bioeconomy institute